THURSDAY, Aug. 4 (HealthDay News) -- Anascorp, the first
injection devised solely to treat scorpion stings, has been
approved by the U.S. Food and Drug Administration.
Venomous scorpions in the United States are primarily found in
Arizona. Severe strings occur most often in babies and children,
causing problems including shortness of breath, fluid in the lungs,
difficulty breathing, increased saliva production, blurred vision
and slurred speech, the agency said in a news release.
Since Anascorp is produced from the blood plasma of horses that
have been immunized with scorpion venom, people who are sensitive
to horse proteins may have an allergic reaction to the product, the
FDA said. The manufacturing process includes steps designed to
decrease the chances of an allergic reaction, and to thwart
transmission of plasma-borne viruses, the agency added.
In clinical testing, Anascorp within four hours reduced
neurological symptoms of scorpion stings among all eight children
treated with the product. But neurological symptoms eased within
four hours in only one of seven children who were given a placebo,
the FDA said.
Reported side effects of Anascorp included vomiting, fever,
rash, nausea, itchiness, headache, runny nose and muscle pain.
Anascorp is licensed to Tennessee-based Rare Disease
Therapeutics, is distributed by Tennessee-based Accredo Health
Group, and is manufactured by Mexico-based Instituto Bioclon.
To learn more about scorpion stings, visit